Zobrazeno 1 - 10
of 176
pro vyhledávání: '"Margaret L. Rand"'
Autor:
Natalie Mathews, Fred G. Pluthero, Margaret L. Rand, Ann Marie Stain, Manuel Carcao, Victor S. Blanchette, Walter H. A. Kahr
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 6, Pp n/a-n/a (2022)
Abstract Background Severe hemophilia A (SHA) patients vary in severity of bleeding, arthropathy, and requirements for replacement factor VIII (FVIII). Baseline hemostatic activity assays using calibrated automated thrombography (CAT) and thromboelas
Externí odkaz:
https://doaj.org/article/f325bf143f5345448cf8b4bac3837d6b
Autor:
Hamzah Khan, Mariya Popkov, Shubha Jain, Niousha Djahanpour, Muzammil H. Syed, Margaret L. Rand, John Eikelboom, C. David Mazer, Mohammed Al-Omran, Rawand Abdin, Mohammad Qadura
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
Approximately 20% of vascular patients treated with acetyl salicylic acid (i.e., aspirin) demonstrate less than expected platelet inhibition – putting them at a four-fold increased risk of adverse cardiovascular events. Low-dose rivaroxaban (2.5 mg
Externí odkaz:
https://doaj.org/article/5d045e46068045dca3609d6940faaeef
Bleeding assessment tools to predict von Willebrand disease: Utility of individual bleeding symptoms
Autor:
Jordan Spradbrow, Sasha Letourneau, Julie Grabell, Yupu Liang, James Riddel, Wilma Hopman, Victor S. Blanchette, Margaret L. Rand, Barry S. Coller, Andrew D. Paterson, Paula D. James
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 1, Pp 92-99 (2020)
Abstract Background Bleeding assessment is part of the diagnostic workup of von Willebrand disease (VWD). Bleeding assessment tools (BATs) have standardized obtaining this information but have been criticized because they are time consuming. Objectiv
Externí odkaz:
https://doaj.org/article/2908119b4e5244759debe0e1f14093fe
Autor:
Hamzah Khan, Abdelrahman Zamzam, Reid C. Gallant, Muzammil H. Syed, Margaret L. Rand, Heyu Ni, Thomas L. Forbes, Mohammed Al‐Omran, Mohammad Qadura
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 8, Pp n/a-n/a (2021)
Abstract Background Aspirin is a key antiplatelet therapy for the prevention of thrombotic events in patients with cardiovascular disease. Studies suggest that ≈20% of patients with cardiac disease suffer from aspirin nonsensitivity, a phenomenon c
Externí odkaz:
https://doaj.org/article/ab319bce541a4d68bc0de4ca85cf7fb6
Autor:
Emily C. Reddy, Margaret L. Rand
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 7 (2020)
The physiological heterogeneity of platelets leads to diverse responses and the formation of discrete subpopulations upon platelet stimulation. Procoagulant platelets are an example of such subpopulations, a key characteristic of which is exposure ei
Externí odkaz:
https://doaj.org/article/a64648f2d5804fe5b22ba8c2cf6257fc
Autor:
Xiaohong Ruby Xu, Yiming Wang, Reheman Adili, Lining Ju, Christopher M. Spring, Joseph Wuxun Jin, Hong Yang, Miguel A. D. Neves, Pingguo Chen, Yan Yang, Xi Lei, Yunfeng Chen, Reid C. Gallant, Miao Xu, Hailong Zhang, Jina Song, Peifeng Ke, Dan Zhang, Naadiya Carrim, Si-Yang Yu, Guangheng Zhu, Yi-Min She, Terry Cyr, Wenbin Fu, Guoqing Liu, Philip W. Connelly, Margaret L. Rand, Khosrow Adeli, John Freedman, Jeffrey E. Lee, Patrick Tso, Patrizia Marchese, W. Sean Davidson, Shaun P. Jackson, Cheng Zhu, Zaverio M. Ruggeri, Heyu Ni
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-18 (2018)
Activation of integrin αIIbβ3 at the surface of platelets is required for their aggregation and for thrombus formation. Here Xu et al. identify apolipoprotein A-IV as a novel ligand for platelet αIIbβ3 integrin, and find it inhibits platelet aggr
Externí odkaz:
https://doaj.org/article/0ce3127e01234b83a479b73aff61e66c
Publikováno v:
Platelets, Vol 29, Iss 1, Pp 27-33 (2018)
Platelets are recognized to be physiologically and functionally heterogeneous. An example of the diversity in reactivity is the formation of a distinct subpopulation of procoagulant phosphatidylserine (PS)-exposing platelets upon activation. Platelet
Externí odkaz:
https://doaj.org/article/8f40658b828445e99b7da76047b40b6d
Autor:
Hamzah Khan, Reid Gallant, Shubha Jain, Mohammed Al-Omran, Charles De Mestral, Elisa Greco, Mark Wheatcroft, Ashraf Alazonni, Rawand Abdin, Margaret L. Rand, Heyu Ni, Mohammad Qadura
Publikováno v:
Medicina, Vol 56, Iss 10, p 519 (2020)
Background and Objectives: Aspirin (acetylsalicylic acid—ASA) is a first-line antiplatelet therapy provided to patients with coronary artery disease (CAD). However, it has been demonstrated that 20–30% of these patients are non-sensitive to their
Externí odkaz:
https://doaj.org/article/651d614c53964075a26c7d36b828c1b8
Autor:
Hamzah Khan, Reid C. Gallant, Abdelrahman Zamzam, Shubha Jain, Sherri Afxentiou, Muzammil Syed, Zachary Kroezen, Meera Shanmuganathan, Philip Britz-McKibbin, Margaret L. Rand, Heyu Ni, Mohammed Al-Omran, Mohammad Qadura
Publikováno v:
Diagnostics, Vol 10, Iss 11, p 871 (2020)
Acetylsalicylic acid (ASA), also known as aspirin, appears to be ineffective in inhibiting platelet aggregation in 20–30% of patients. Light transmission aggregometry (LTA) is a gold standard platelet function assay. In this pilot study, we used LT
Externí odkaz:
https://doaj.org/article/28011d2e14bb436b81c692c06c0d424f
Autor:
Denisa Urban, Fred G. Pluthero, Hilary Christensen, Shoma Baidya, Margaret L. Rand, Animitra Das, Prakeshkumar S. Shah, David Chitayat, Victor S. Blanchette, Walter H.A. Kahr
Publikováno v:
Haematologica, Vol 102, Iss 2 (2017)
Externí odkaz:
https://doaj.org/article/6fc4307c758d41d6a5e5489204d8d23d